Correction: Real-World Evidence on the Clinical Efficacy of Long-Acting Injectable Antipsychotics for Schizophrenia Spectrum Disorders - Scorecard - MDSpire
Clinical Scorecard: Correction: Real-World Evidence on the Clinical Efficacy of Long-Acting Injectable Antipsychotics for Schizophrenia Spectrum Disorders
At a Glance
Category
Detail
Condition
Schizophrenia Spectrum Disorders
Key Mechanisms
Long-acting injectable antipsychotics
Target Population
Patients with schizophrenia spectrum disorders
Care Setting
Outpatient and inpatient psychiatric care
Key Highlights
Correction of p-value from <0.17 to <0.017
Focus on long-acting injectable antipsychotics
Real-world evidence supports clinical efficacy
Guideline-Based Recommendations
Diagnosis
Assess clinical symptoms and history for schizophrenia spectrum disorders
Management
Consider long-acting injectable antipsychotics for treatment adherence
Monitoring & Follow-up
Regularly evaluate patient response and side effects
Risks
Monitor for potential adverse effects associated with antipsychotic medications
Patient & Prescribing Data
Individuals diagnosed with schizophrenia spectrum disorders
Long-acting injectable formulations may improve adherence and outcomes
Clinical Best Practices
Utilize long-acting injectable antipsychotics for patients with adherence challenges
Incorporate patient education on the benefits of long-acting treatments
Regular follow-up to assess treatment efficacy and side effects
Swedish study finds two-way associations between premenstrual disorders and psychiatric conditions, with strongest links involving depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, and personality disorders.
